Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexmecamylamine - Atacama Therapeutics

Drug Profile

Dexmecamylamine - Atacama Therapeutics

Alternative Names: AT-5214; Dexmecamylamine hydrochloride; NIH-11008; S-mecamylamine; TC-5214

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of South Florida Research Foundation
  • Developer AstraZeneca; Atacama Therapeutics; Targacept
  • Class Antidepressants; Norbornanes; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha3beta4 nicotinic receptor antagonists; Alpha4beta2 nicotinic receptor antagonists; Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperhidrosis
  • Discontinued Hypertension; Major depressive disorder; Overactive bladder; Resistant hypertension

Most Recent Events

  • 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
  • 03 Sep 2021 Phase II development for Hyperhidrosis is ongoing in USA (Atacama Therapeutics pipeline, September 2021) (NCT04263623)
  • 20 Jul 2021 Atacama Therapeutics completed enrolment in the phase II trial for Hyperhidrosis (Treatment-naive) in USA (PO) (NCT04263623)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top